Vanguard Group’s China Biologic Products Holdings CBPO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
– Sell
-769,761
Closed -$91.1M – 4502
2021
Q1
$91.1M Buy
769,761
+22,696
+3% +$2.68M ﹤0.01% 2000
2020
Q4
$88.2M Sell
747,065
-94,252
-11% -$10.9M ﹤0.01% 1895
2020
Q3
$93.5M Sell
841,317
-69,091
-8% -$7.42M ﹤0.01% 1717
2020
Q2
$93M Sell
910,408
-82,235
-8% -$8.8M ﹤0.01% 1718
2020
Q1
$107M Hold
992,643
– – ﹤0.01% 1489
2019
Q4
$110M Buy
944,591
+43,921
+5% +$5.09M ﹤0.01% 1700
2019
Q3
$103M Sell
900,670
-49,751
-5% -$4.95M ﹤0.01% 1709
2019
Q2
$90.6M Buy
950,421
+29,178
+3% +$2.75M ﹤0.01% 1803
2019
Q1
$84.1M Buy
921,243
+21,651
+2% +$1.77M ﹤0.01% 1836
2018
Q4
$68.3M Buy
899,592
+26,040
+3% +$1.92M ﹤0.01% 1871
2018
Q3
$69.9M Buy
873,552
+90,532
+12% +$8.44M ﹤0.01% 1981
2018
Q2
$77.8M Buy
783,020
+70,776
+10% +$6.12M ﹤0.01% 1895
2018
Q1
$57.7M Buy
712,244
+12,616
+2% +$1.02M ﹤0.01% 2000
2017
Q4
$55.1M Buy
699,628
+162,995
+30% +$13.6M ﹤0.01% 2013
2017
Q3
$49.5M Buy
536,633
+512,947
+2,166% +$49.3M ﹤0.01% 2048
2017
Q2
$2.68M Buy
23,686
+19,169
+424% +$2.14M ﹤0.01% 3293
2017
Q1
$452K Hold
4,517
– – ﹤0.01% 3776
2016
Q4
$486K Buy
4,517
+17
+0.4% +$1.99K ﹤0.01% 3741
2016
Q3
$560K Hold
4,500
– – ﹤0.01% 3738
2016
Q2
$478K Hold
4,500
– – ﹤0.01% 3806
2016
Q1
$515K Buy
4,500
+1,000
+29% +$117K ﹤0.01% 3785
2015
Q4
$499K Hold
3,500
– – ﹤0.01% 3833
2015
Q3
$314K Buy
+3,500
New +$369K ﹤0.01% 3958

Vanguard Group's CBPO Position: Q2 2021 in Review

Vanguard Group sold out of China Biologic Products Holdings (CBPO) in Q2 2021, closing a stake of 769,761 shares — an estimated $91.1M sold.

Vanguard Group first reported a position in CBPO in Q3 2015 and held it in 23 quarters. The position peaked at $110M in Q4 2019. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.

  • Vanguard Group reported no remaining China Biologic Products Holdings position as of Q2 2021 after selling out during the quarter.
  • Vanguard Group sold 769,761 China Biologic Products Holdings shares in Q2 2021, an estimated $91.1M.
  • Vanguard Group first reported a position in China Biologic Products Holdings in Q3 2015 and held it in 23 quarters.
  • Vanguard Group's China Biologic Products Holdings position peaked at $110M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held China Biologic Products Holdings as of Q2 2021.

Based on Vanguard Group's 13F filing for Q2 2021, filed 13 Aug 2021.